Recent News

• 09.15.2025 - Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
• 09.15.2025 - Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
• 08.11.2025 - Humacyte Second Quarter 2025 Financial Results and Corporate Update
• 08.11.2025 - Humacyte Second Quarter 2025 Financial Results and Corporate Update
• 08.11.2025 - Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
• 08.11.2025 - Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
• 08.07.2025 - Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
• 08.07.2025 - Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
• 07.23.2025 - Humacyte Announces First Symvess™ Sale to Military Treatment Facility
• 07.23.2025 - Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Recent Filings

• 09.12.2025 - S-3 Registration statement under Securities Act of 1933
• 08.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.20.2025 - 144 Report of proposed sale of securities
• 08.19.2025 - 144 Report of proposed sale of securities
• 08.18.2025 - 144 Report of proposed sale of securities
• 08.11.2025 - 8-K Current report
• 08.11.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]